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Background: Peripheral arterial disease (PAD) is associated with an excessive risk for cardiovascular events and mortality.
To determine measures prognostic of adverse events, ankle-brachial index (ABI) was compared with dobutamine stress
echocardiography (DSE) in patients referred to our vascular center for the evaluation of PAD.
Methods: The medical records of consecutive patients referred for the concurrent evaluation of PAD and coronary artery
disease (CAD) between 1992 and 1995 were reviewed for subsequent cardiovascular events and death.
Results: Among 395 patients (mean age, 69.7  9.6 years; 40% women), 341 had abnormal ABI and 268 had abnormal
DSE (95 fixed and 173 stress-induced wall motion abnormalities). During a mean follow-up of 4.7 years, 27.3% of
patients experienced a cardiovascular event, and 39.4% died. By multivariate analysis, ABI provided the strongest
prediction of all-cause mortality (hazard ratio [HR], 2.34; 95% confidence interval [CI], 1.36 to 4.05; P  .002).
Conversely, DSE with inducible or fixed wall motion abnormalities showed no association with cardiovascular events or
increased mortality in multivariate analysis. The only DSE variable independently predictive of mortality was decreased
left ventricular ejection fraction (<50%) at peak stress (HR, 1.70; 95% CI, 1.22 to 2.36; P  .002). Statin and aspirin
therapy, but not -blockers, were protective. There was no relation between ABI and wall motion index score at rest or
after stress.
Conclusions: In high-risk patients referred to our vascular center for the evaluation of PAD, the assessment of ABI
provided a strong independent prediction of all-cause mortality. Therefore, proper interpretation of this simple,
affordable, and reproducible measure extends beyond the assessment of PAD severity. Although a poor left ventricular
response to dobutamine was also predictive, other echo variables were not. ( J Vasc Surg 2007;46:62-70.)Peripheral arterial occlusive disease (PAD) is prevalent
in Western societies.1 PAD manifested as claudication is
found in 3.7% of people aged between 60 and 70 years old
and in 5.2% of those 70 years old,2 but the incidence of
asymptomatic disease is approximately five times higher.3
Atherosclerosis is a generalized process involving different
arterial territories, therefore it is not surprising that the
presence of flow-limiting lesions in a peripheral artery indi-
cates disease in coronary, renal, and carotid arteries.4 PAD
is an independent predictor of early5 and late6 cardiovascu-
lar complications and death. Consequently, individuals
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62with PAD are among the highest-risk vascular patients, and
a cost-effective strategy is required for their evaluation and
treatment.
Ankle-brachial index (ABI) is not only widely used as a
noninvasive test for PAD7 but is also an independent pre-
dictor of cardiovascular risk.8-10 However, the utility of this
measure as a predictor of cardiovascular event andmortality
has recently been questioned, particularly among patients
with multiple atherosclerotic risk factors or established
vascular disease.11 Furthermore, in patients with PAD, it is
unclear whether more extensive and sophisticated cardiac
testing adds useful prognostic information once the ABI is
known.
Dobutamine stress echocardiography (DSE) detects
coronary artery disease (CAD) without walking exercise
and is therefore very useful in patients with PAD.12-15 DSE
is used to define preoperative cardiovascular risk in patients
undergoing noncardiac surgery16,17 and is also an indepen-
dent predictor of late coronary events.18,19
Our first objective was to determine if ABI predicts
cardiovascular morbidity and all-cause mortality in a se-
lected, comprehensively evaluated group of high-risk pa-
tients. Our second objective was to compare the predictive
value of low ABI with positive DSE and other clinical and
therapeutic variables for cardiovascular morbidity and all-
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dicts positive DSE, we wanted to challenge the general
opinion that low ABI predicts cardiovascular morbidity and
mortality because it selects patients with particularly severe
coronary disease.
METHODS
Study population. All patients undergoing assess-
ment of PAD by ABI measurement between November 1,
1992, and May 31, 1995 at the Vascular Laboratory of
Gonda Vascular Center and who also had DSE testing 6
months of their vascular evaluation were included. The
study was approved by the Mayo Clinic Institutional Re-
view Board. Data were collected from a centralized system
that contains records of all patients treated and followed up
at Mayo Medical Center. It includes the details for every
inpatient hospitalization, outpatient visit, radiology exam-
ination, all laboratory and pathology results, death certifi-
cates, and relevant correspondence.
The follow-up period began at the time of the initial
patient encounter and ended with the most recent medical
evaluation or time of death. Causes of death were deter-
mined by a review of medical records, death certificate or
United States Social Security Death Index, and autopsy
results, when available.
Diabetes mellitus was diagnosed from the criteria rec-
ommended by the American Diabetes Association,20 and
dyslipidemia according to recommendations of the Na-
tional Cholesterol Education Program expert panel and the
American College of Physicians.21 Prior CAD was recog-
nized when a patient had clinical symptoms of angina and a
confirmatory test result (abnormal electrocardiogram, pos-
itive cardiac stress test, abnormal coronary angiogram), or
had had a previous myocardial infarction (MI), percutane-
ous coronary intervention, or coronary artery bypass graft.
We used a control group constructed on the basis of
age-specific and sex-specific mortality rates in the United
States white population for the period of this study.22 We
assumed that the expected survival rate accounts for the
effects of other medical conditions according to their
known prevalence in this reference population.
Ankle-brachial measurement. The ABI was mea-
sured according to a standard protocol used at the Gonda
Vascular Center, Mayo Clinic, as previously described.23
Briefly, blood pressures were measured with the patient in
the supine position by using a 8.3-MHz continuous wave
Doppler probe over each ankle from both dorsalis pedis and
posterior tibial arteries and in the brachial artery of each
arm. The greater of ankle systolic to the greater of brachial
systolic pressures were used to calculate the ratio. If bilat-
eral disease was present, the lower ratio was taken for study
analysis.
All the test results were interpreted by physician from
the Mayo Clinic Vascular Laboratory and subsequently
reviewed by the study vascular physician (W. E. W.). An
ABI 0.9 was defined as abnormal.8 For the purpose of
data analysis, the abnormal ABI group was further dividedinto mild PAD (ABI, 0.8 to 0.9), moderate PAD (ABI, 0.5
to 0.8), and severe PAD (ABI 0.5).
Dobutamine stress echocardiography. DSE was
performed according to a previously described protocol.24
The left ventricular ejection fraction was evaluated by a
modified method of Quinones et al25 or by visual estima-
tion.Wall motion was assessed at rest and with stress in each
of 16 segments by using a scale of 1 through 5, in which 1
normal, 2  hypokinesis, 3  akinesis, 4  dyskinesis, and
5  aneurysm. The wall motion score index was calculated
at rest and during stress by dividing the total wall motion
severity score by the number of measured segments.26
For the purpose of this study, the rest and stress images
were analyzed for inducible myocardial ischemia and the
presence of fixed abnormalities. Ischemia was diagnosed
when new or worsening wall motion abnormalities were
observed with stress, and defined as positive DSE for myo-
cardial ischemia or simply positive DSE. Fixed wall motion
abnormalities were those present at rest and unchanged
with stress. DSE was considered abnormal in the presence
of ischemia or fixed wall motion abnormalities. Results
were interpreted by a cardiologist from the Mayo Clinic
Echocardiography Laboratory and subsequently analyzed
by the study cardiologist (P. A. P.).
Study end points, major event definition. Study end
points incorporated cardiovascular events and death. Car-
diovascular events included stroke, transient ischemic at-
tack (TIA), unstable angina, andMI. Criteria to define MI,
unstable angina, stroke, and TIA were adapted from those
proposed by the American Heart Association.27
Statistical methods. Continuous variables were re-
ported as mean  SD and categoric variables as percent-
ages. Univariate andmultivariate associations of clinical and
echocardiographic variables were assessed with Cox pro-
portional hazards models for the two end points of first
cardiovascular adverse event and all-cause mortality. In the
multivariate models, variables were chosen in a forward
selection manner, with entry and retention in the model set
at a significance level of 0.15 and 0.05, respectively.
The multivariate models were constructed in two steps:
(1) fitting a multivariate model of only clinical and echo-
cardiographic data and (2) evaluating the association of the
variables of interest and their interaction. In the second,
step three variables were added to the constructed model,
one for abnormal ABI, one for positive DSE, and one for
their interaction. The interaction term was not significant
in any of the two multivariate models, thus it was removed
from the final models.
The results of these analyses were summarized as haz-
ard ratios (HR) with 95% confidence intervals (CI). End
point-free survivals were estimated by use of the Kaplan-
Meier method. Expected survival was compared with ob-
served using the one-sample log-rank test. Two-sided val-
ues of P  .05 were considered statistically significant. All
analyses were done using SAS 8 software (SAS Institute,
Cary, NC).
orma
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Demographic and clinical characteristics. Between
November 1, 1992, and May 31, 1995, 437 patients
underwent ABI measurement and DSE testing 6
months of their vascular evaluation for various clinical
indications, including preoperative evaluation for major
noncardiac surgery (71%), risk stratification for known
CAD (11%), evaluation of chest pain (11%), or other
(7%). Of these, 42 patients were excluded because of
noncompressible arteries (n  23), incomplete vascular
laboratory evaluation (n  5), or poor-quality baseline
echocardiographic images (n  14). Therefore, 395
patients were included into the analysis.
Demographic and clinical data of this group are sum-
marized in Table I. Cardiovascular risk factors were preva-
lent in this cohort, with 83.3% having more than three
atherosclerotic risk factors. The two most common risk
factors were tobacco use and hypertension. One third of
patients received statin therapy, and nearly 75% received
antiplatelet therapy, principally aspirin. No relationship was
found between DSE results (positive, negative, abnormal,
normal) and therapy with -blockers, statins, or antiplatelet
agents by statistical modeling. Those individuals with both
an abnormal ABI and a positive DSE more often had
diabetes, history of MI, and documented carotid artery
disease relative to those with a negative DSE (P  .05 for
each comparison).
Ankle-brachial index. Abnormal ABI was found in
341of patients (86%), and the mean ABI value for the
whole study group was 0.5  0.3. Within the abnormal
ABI group, 23 (6%) had mild PAD (ABI, 0.8 to 0.9), 123
(31%) hadmoderate PAD (ABI, 0.5 to 0.8), and 195 (49%)
had severe PAD (ABI 0.5) The Rutherford classifica-
tion, which combines clinical features and ABI values,28
Table I. Demographic and clinical characteristics
ABI
All patients All Positive
Patient total 395 341 153
Age (years) 69.7  10 69.7  10 70.4
(%) Male 60.4 61.3 67.
Current/former smokers 81.1 83 84.
Hypertension 76 78 82.
Diabetes mellitus 34.1 35.2 42.
Dyslipidemia 60.4 60.4 64.
3 CAD risk factors 83.3 85 91.
Known CAD 64.9 66 78.
Previous Ml 26 26.1 34
Carotid disease 42.4 44.6 52.
Atrial fibrillation 14.1 15.2 13.
Antiplatelet therapy 72.2 73.9 76.
ACE/ARB therapy 52 52.8 53.
-Blocker therapy 44.9 45.5 47.
ABI, Ankle-brachial index;DSE, dobutamine stress echocardiography;CAD
enzyme; ARB, angiotensin-receptor blocker.
*Significant (P  .05) difference between the patients with abnormal and nwas calculable for 305 symptomatic patients. Ulcer-ation/tissue loss (classes V and VI) was present in 88
patients, rest pain (class IV) in 29, severe claudication
(class III) in 177, but only 11 had mild-to-moderate
claudication (classes I and II).
Dobutamine stress echo. Among the 395 patients,
mean left ventricular ejection fraction at rest was 53.7% 
12% (range, 13% to 75%), and the mean wall motion score
at rest was 1.36 0.48 (range, 1.00 to 3.00). Wall motion
abnormalities were present in 24.8%  30.9% of segments
(median, 12.5%) during the resting study. DSE was normal
in 127 and abnormal in 268 patients (68%). Of the 268
patients with abnormal studies, 173 had dobutamine-
induced ischemia. Among those with inducible ischemia,
resting wall motion abnormalities were present in 131
(76%), and the remaining 95 patients had fixed wall motion
abnormalities with no inducible ischemia.
Cardiovascular morbidity and all-cause mortality.
Themean duration of follow up was 4.7 4 years (median,
4.1 years; range, 0.0 to 11.8 years). The predicted 5-year
rates were 27.3% for a cardiovascular event and 39.4% for
mortality (Table II). Patients with an abnormal ABI expe-
rienced nearly twice as many cardiovascular events than did
individuals with normal ABI. Furthermore, cerebral isch-
emic events were 3.75-fold more common in those patients
with an abnormal ABI. All cause mortality was twofold
higher in this group. In those patients with abnormal DSE
(both inducible and fixed wall motion abnormalities), car-
diovascular events and all cause mortality were increased by
1.6-fold. Cerebral ischemic events were not predicted by
DSE results.
Predictors of cardiovascular morbidity and all-
cause mortality. Log-rank test analysis demonstrated that
abnormal ABI was associated with significantly higher rate
of cardiovascular events (P  .02) and all-cause mortality
ABI 0.9
Negative DSE All Positive DSE Negative DSE
188 54 20 34
69.1  10 69.2  8 69.4  6 69.1  9
56.4 55.6 70 47.1
81.9 70.4 80 64.7
74.5 64.8 50 73.5
29.3 27.8 40 20.6
56.9 59.3 65 55.9
79.8 74.1 80 70.6
55.9 59.3 75 50
19.7 25.9 45 14.7
38.3 29.6 25 32.4
17 7.4 0 11.8
71.8 61.1 85 47.1
52.1 48.1 60 41.2
44.1 42.6 55 35.3
nary artery disease;MI,myocardial infarction;ACE, angiotensin-converting
l DSE who had ABI 0.9.0.9
DSE
 9
3*
3
4
5*
7
5*
4*
3*
1
5
6
1
, coro(P  .001) vs normal ABI (Fig 1). Positive DSE (inducible
yoca
xed w
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nificantly increased rate of mortality or cardiovascular
events compared with negative DSE (Fig 2, A and B). DSE
with fixed wall motion abnormalities showed no association
with increased rate of cardiovascular events or mortality
(data not shown). However, when the combined group of
inducible and fixed wall motion abnormalities (abnormal
DSE) was compared with normal DSE, a borderline higher
cardiovascular event rate (P  .052), and significantly
worse survival (P  .02) was found (Fig 2, C and D).
When our study patients were compared with the data
from our population-based cohort matched for age and
gender, an abnormal ABI was associated with worse sur-
vival (P .001). Our study patients with normal ABI had a
nonstatistically significant trend toward worse survival (P
.069), and this trend might have reached significance if our
group had included more patients with normal ABI. In
addition, both abnormal and normal DSE were associated
with worse than expected survival (P  .001).
Univariate regression analysis showed that ABI, dia-
Table II. Predicted percent of patients with cardiovascula
All patients ABI 0.9
395 341
Unstable angina/MI 18.6 19.7
Stroke/TIA 12.1 13.5
Patients with CV event 27.3 29.2
All-cause deaths 39.4 42.3
ABI, Ankle-brachial index;DSE, dobutamine stress echocardiography;MI,m
*Positive DSE (inducible wall motion abnormalities) in 176 patients plus fi
Fig 1. Kaplan-Meier analysis of (A) survival free from th
ankle-brachial index (ABI, solid line), abnormal ABI (da
(expected) was constructed on the basis of age-specific
population for the period of this study.betes mellitus, presence of3 cardiovascular risk factors,history of CAD, previous MI, carotid disease, therapy
with -blockers, angiotensin-converting enzyme inhibi-
tors (ACE)/angiotensin receptor-blockers (ARB) ther-
apy, and abnormal wall-motion score index at stress were all
predictors of cardiovascular event (data not shown). How-
ever, after adjustment for other clinical variables, only ca-
rotid disease, diabetes mellitus, 3 cardiovascular risk fac-
tors, and unexpectedly, also treatment with -blockers,
were found to be statistically significant predictors of a
cardiovascular event (Table III). Abnormal ABI did not
predict a cardiovascular event. Neither inducible wall motion
abnormalities (positive DSE) nor inducible and fixed wall
motion abnormalities jointly (abnormal DSE) predicted car-
diovascular event by multivariate analysis (Table III).
Treatment with -blockers, antiplatelet agents, and
statins was associated with improved survival by univariate
analysis (data not shown). ABI, age, diabetes mellitus,
dyslipidemia, history of CAD, left ventricular end-systolic
volume at rest or peak stress, left ventricular ejection frac-
tion at rest or peak stress, wall-motion score indices at rest
rbidity and all-cause mortality at 5 years
ABI 0.9 DSE abnormal* DSE normal
54 268 127
12.7 21.3 13.4
3.6 11.2 14.2
16.6 31.2 19.5
21.0 44.5 28.3
rdial infarction; TIA, transient ischemic attack; CV, cardiovascular accident.
all motion abnormalities in 95 (n  268).
cardiovascular event and (B) overall survival, for normal
ine), and control group (dotted line). The control group
sex-specific mortality rates in the United States whiter moe first
shed l
andor peak stress, and presence of left ventricular ejection
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all-cause mortality by univariate analysis (data not shown).
By multivariate analysis (Table III), ABI was the strongest
predictor of all-cause mortality (HR, 2.34; 95% CI, 1.36 to
4.05; P  .002). Statin therapy was the most protective
variable (HR, 0.28; 95% CI, 0.20 to 0.39; P  .001), and
treatment with antiplatelet agents also appeared to be pro-
tective. Age, diabetes mellitus, history of CAD, and left
ventricular ejection fraction 50% at peak stress predicted
mortality after adjustment for other clinical variables. In
multivariate analysis, neither positive nor abnormal DSE
predicted all-cause mortality (Table III).
DSE test results were abnormal in 286 patients (95
fixed and 173 stress-induced wall motion abnormalities),
and 69 (26%) underwent catheter-based or surgical coro-
nary revascularization. Cardiovascular event rates and mor-
tality, however, were similar for those patients undergoing
coronary revascularization compared with those treated
conservatively (data not shown). Of the 61 patients who
underwent vascular surgical intervention, 20 (15.7%) of
127 had a normal and 41 (15.2%) of 268 had abnormal
preoperative DSE results. The cardiovascular morbidity
and all cause mortality were similar in both groups.
Effect of peripheral artery disease severity on study
end points. To assess the effect of PAD severity on out-
Fig 2. Kaplan-Meier analysis of (A and C) survival fre
survival . A andB, Positive dobutamine stress echocardiog
D,Abnormal DSE (dashed line), normal DSE (solid line),
was constructed on the basis of age-specific and sex-specifi
period of this study.comes, we analyzed predictive power of ABI along thewhole spectrum of its value. Significant worsening of all-
cause mortality (P  .001) and trend towards worse sur-
vival free from cardiovascular event (P  .07) were ob-
served with decrease of ABI by log-rank test analysis (Fig 3,
A and B).
Correlation between ankle-brachial index and do-
butamine stress echocardiography. To determine the
association between flow-limiting lesions in peripheral and
coronary circulation, we compared ABI value with DSE
wall motion score index at stress. A complete lack of corre-
lation between these measures is readily apparent (Fig 4).
Indeed, no correlation was found between ABI and any of
the echocardiographic variables assessed, including pres-
ence of ischemia, abnormal study, or change in wall motion
score index with stress (data not shown).
DISCUSSION
This present study confirms the poor prognosis for
patients with PADwho have undergone objective testing of
both the coronary (DSE) and peripheral circulation (ABI):
nearly 67% experienced a cardiovascular event or died 5
years. Multiple cohort studies7,9-12 and subanalyses of cor-
onary trials5,29-32 have shown that the presence of PAD
predicts cardiovascular morbidity and mortality, but all
these studies had incomplete assessment of either coronary
m the first cardiovascular event and (B and D) overall
y (DSE, dashed line) and negativeDSE (solid line).C and
ontrol group (dotted line).The control group (expected)
rtality rates in the United States white population for thee fro
raph
and c
c moor peripheral circulations. Moreover, PAD was defined in
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therein had combined cerebral atherosclerosis, aortic aneu-
rysmal disease, and PAD into one category. This mixture
conveys different clinical meaning, because the potential
direct cardiovascular complications of carotid disease or
abdominal aortic aneurysm are quite different than leg
ischemia. Also, the lack of ABI evaluation in “coronary”
series makes it very likely that about 25% of “cardiac cases
without PAD” had indeed either nondiagnosed or asymp-
tomatic PAD.2-4,6-11
ABI was the strongest independent predictor of all-
cause mortality in patients with extensive PAD. Previous
studies have had conflicting results: some reported a lack of
predictive power for ABI11,33 and others found a significant
association between abnormal ABI and cardiovascular
events and mortality.6-10 This study also demonstrated that
PAD severity correlates with an unfavorable outcome. The
log-rank test illustrated a definite trend of increasing risk of
death with decreasing values of ABI. This observation of
inverse relation of ABI values and adjusted risk of mortality
is in agreement with previous reports.8-10
We now show that beyond defining the location and
severity of PAD, ABI provides important prognostic infor-
mation in high-risk patients. This is important clinically
because the ABI is a well-established, reproducible, and
inexpensive test that requires little training and few re-
sources to perform.7 Although ABI was designed for both
disease identification and quantitative severity staging, its
Table III. Multivariate analysis of demographic, clinical,
and echocardiographic variables for prediction of first
cardiovascular event and all-cause mortality
Variable HR 95% CI P
Cardiovascular event
Diabetes 1.55 1.02-2.35 .04
Carotid bruit 2.01 1.32-3.05 .001
CV risk factors 3 1.93 0.90-4.17 .09
-Blockers therapy 1.77 1.17-2.67 .006
Abnormal ABI* 1.69 0.81-3.55 .17
Positive DSE† 1.13 0.76-1.68 .56
Abnormal DSE‡ 1.33 0.86-2.08 .20
All-cause mortality
Age 1.04 1.03-1.06 .001
Diabetes 1.84 1.37-2.48 .001
Previous CAD 1.43 1.04-1.98 .028
Antiplatelet therapy 0.64 0.46-0.90 .009
Statin therapy 0.28 0.20-0.39 .001
LVEF  50 at peak stress 1.7 1.22-2.36 .002
Abnormal ABI* 2.34 1.36-4.05 .002
Positive DSE† 1.16 0.86-1.57 .32
Abnormal DSE‡ 1.11 0.79-1.57 .55
HR, Hazard ratio; CI, confidence interval; CV, cardiovascular; ABI, ankle-
brachial index; DSE, dobutamine stress echocardiography; CAD, coronary
artery disease; LVEF, left ventricular ejection fraction.
*ABI 0.9.
†DSE with new or worsening wall motion abnormalities at stress.
‡Combined group of positive DSE and DSE with fixed wall motion abnor-
malities (present at rest and unchanged with stress).apparent association with cardiovascular events and mortal-ity may be of additional benefit. The prognostic strength of
ABI assessment is evident in this data set, despite the
inclusion of a relatively small number of subjects with
normal ABI.
To our knowledge, this is the first study to assess the
prognostic value of DSE in patients referred for ABI. DSE
is an established method for evaluation of myocardial isch-
emia,12-15 with published diagnostic sensitivities (74% to
89%) and specificities (82% to 88%) similar to other meth-
ods of stress imaging. A meta-analysis of 28 separate stud-
ies12 showed that the mean sensitivities of DSE for single-
vessel, double-vessel, and triple-vessel obstructive coronary
disease were 74%, 86%, and 92%, respectively. Moreover,
DSE has shown prognostic value in predicting cardiac
events extending out to 5 years in prior studies of patients
undergoing elective noncardiac surgery.16-19
In this high-risk patient population with PAD, DSE
positive for myocardial ischemia or DSE that demonstrated
fixed wall motion abnormalities did not predict cardiovas-
cular events or all-cause mortality when analyzed sepa-
rately. When inducible ischemia and fixed wall motion
abnormalities were analyzed together by log-rank test,
abnormal DSE showed association with increased mortality
(P  .02) and a borderline association (P  .052) with
cardiovascular events. However, abnormal DSE lost its
predictive power after adjustment for other clinical vari-
ables. The only DSE variable that independently predicted
all-cause mortality was a reduced ejection fraction at peak
stress.
In a previous large study of patients with PAD,19 DSE
provided incremental prognostic information beyond that
provided by clinical and echocardiographic data for predict-
ing mortality and cardiac morbidity, including MI and
coronary revascularization. In contrast to the current study,
this previous report did not include stroke, TIA, or unstable
angina among cardiac events; these events may be better
predicted by ABI (see also Table II).
The last but also very important finding of this study
was the lack of correlation between ABI and DSE results.
This showed that the presence of more severe PAD did not
predict the presence of more severe CAD. Previously, Pa-
pamichael et al33 reported a relationship between ABI and
the extension of CADmeasured by the number of diseased
coronary arteries and Gensini angiographic score, but the
mean ABI value for this study group was normal (0.93):
only 27 patients (16%) had an ABI0.9. In fact, this study
established a connection between the severity of CAD and
the presence (ABI 0.9) or absence (ABI 0.9) of PAD,
but not its gravity. A number of coronary trials5,29,33
showed that patients with CAD and PAD disease had more
advanced CAD disease than CAD patients without PAD,
but some also reported an identical30,31 or nearly the
same32 angiographic picture of coronary circulation in both
groups. It is well established that PAD patients die primar-
ily from cardiac causes.3-6,8-11,29-33
The fact that DSE measures predicting poor outcome
were those indicating the presence of CAD, but not those
associated with its acute pathophysiologic significance, and
atien
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long-term outcomes in our patients implies that factors
other than current myocardial ischemia predict future
atherothrombotic events in these patients.
The presence of PAD detected by an abnormal ABI
indicates the presence of enormous plaque burden with
large areas of atherosclerotic vessel wall in continuity with
flowing blood. The iliofemoral and femoropopliteal arterial
segments have surface areas that are orders of magnitude
larger than that of the coronary arteries; therefore, athero-
sclerosis in these segments may be associated with much
greater activation of the coagulation system. Indeed, previ-
ous studies reported positive correlation between increas-
ing burden of atherosclerotic disease and the rate of cardio-
vascular complications.34
Increased platelet and coagulation cascade activation
were also found in patients with PAD.35 Shankar et al36
Fig 3. Kaplan-Meier analysis of (A) survival free from th
vascular studies (ankle-brachial index [ABI] 0.9), and
(ABI  0.5) peripheral arterial disease. *Only 23 (6%) p
Fig 4. Linear regression analysis of the correlation between wall
motion score index at stress and ankle-brachial index values.showed that blood coagulability increased as it flowedthrough an atherosclerotic iliac artery, and the magnitude
of that change was related to the severity of stenosis. It
therefore seems likely that a significant cause of the mor-
bidity and mortality associated with PAD could be related
to thrombosis. Our analysis showed that antiplatelet ther-
apy significantly improved survival in PAD patients.
The Clopidogrel Versus Aspirin in Patients at Risk of
Ischaemic Events (CAPRIE) study37 and, more recently,
the Clopidogrel for the Reduction of Events During Ob-
servation (CREDO) trial38 showed that intensive antiplate-
let therapy is associated with a significantly greater reduc-
tion in cardiovascular events and mortality in patients with
PAD compared with all cardiovascular disease patients. The
Clopidogrel and Aspirin versus Aspirin Alone for the Pre-
vention of Atherothrombotic Events (CHARISMA) trial39
revealed no advantage of combined clopidogrel and aspirin
versus aspirin alone therapy in cardiovascular patients, but
there was no separate analysis for PAD patients.
In our study, statin therapy also showed profound
impact on mortality, which may not only reflect prevention
of burden growth but also the antithrombotic potential of
these medications.40
If proven in a well-designed prospective trial, our hy-
pothesis that the mere presence of a critical atherosclerotic
burden is sufficient to enhance coagulation and effect sur-
vival would lead to a significant modification in the treat-
ment of atherosclerosis and in secondary prophylaxis after
cardiovascular events. In fact, we plan to initiate a prospec-
tive trial in which we would use computed tomography
angiography to measure the total atherosclerotic burden
and associated laminated thrombus in PAD patients and
correlate these measurements with platelet and coagulation
t cardiovascular event and (B) overall survival for normal
(ABI 0.8 to 0.9), moderate (ABI 0.5 to 0.8), and severe
ts had mild peripheral arterial disease.e firs
mildsystem activation as well as morbidity and mortality.
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limitations that should be highlighted. First, this study was
neither prospective nor population-based and was con-
ducted on a selected group of high-risk patients with
known or suspected CAD referred to a tertiary care center
for evaluation of PAD, and thus, our results may not be
directly extrapolated to the population in general. How-
ever, the intent of this study was to provide information
relevant to risk stratification for patients with PAD. With
the aging of our population and the growing epidemic of
atherosclerosis, the relevance of this data is anticipated to
increase. Diabetic patients with noncompressible arteries or
those patients for whom ABI assessment cannot be per-
formed owing to painful limb ulceration represent unique
circumstances for which this data may further not apply.
Second, death certificates and autopsy reports were not
universally available, so our analysis was restricted to all-
cause mortality, which limited our ability to parse cardio-
vascular and noncardiovascular causes of death.
Third, the retrospective nature of this study will only
permit speculation about how the clinician altered the
medical management of these patients based on results of
DSE. We could not establish a relationship between DSE
results (positive, negative, abnormal, normal) and therapy
with -blockers, statins, or antiplatelet agents by statistical
modeling. Nonetheless, the beneficial impact of both statin
and antiplatelet therapy must be underscored for these
patients with peripheral arterial occlusive disease, regardless
of severity.
CONCLUSION
The present study confirms a poor prognosis in PAD,
shows that in this selected group of high-risk patients ABI is
an independent predictor of all-cause mortality, and dem-
onstrates a correlation between the severity of PAD and
survival. Conversely, DSE with inducible or fixed wall
motion abnormalities showed no association with cardio-
vascular events or increased mortality in multivariate anal-
ysis. The lack of correlation between the severity of PAD (as
measured by ABI) and CAD (as measured by DSE) sug-
gests that in high-risk patients, low ABI may not predict
more advanced CAD.
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This study by Dr Thatipelli and colleagues from the Mayo
Clinic is a complex analysis that rewards careful reading and
analysis. A brief summary of their findings is important. By life table
analysis, abnormal ankle brachial index (ABI) was associated with
higher rates of both cardiovascular morbidity (CVM) (P.02) and
all-cause mortality (ACM) (P  .001). Positive dobutamine stress
echocardiography (DSE) (inducible wall motion abnormality) was
not associated with increased rates of either CVM or ACM, while
abnormal DSE (either inducible or fixed wall motion abnormality)
was associated with a trend toward a higher CVM (P .052), and
with higher ACM (P  .02). Furthermore, when tested by multi-
variate regression analysis, abnormal ABI held the strongest asso-
ciation with ACM, while neither positive nor abnormal DSE
studies were associated with significantly increased ACM. Also
coronary intervention (percutaneous transluminal coronary angio-
plasty and stenting or coronary artery bypass grafting in 69 trial
patients) did not influence the incidence of CVM or ACM. Finally,
there was no correlation between ABI and severity of induced wall
motion abnormalities.
So, what does all this mean? The authors argue plausibly that
abnormal ABI is a measure of increased total atherosclerotic bur-
den, positive DSE is a measure of the acute pathophysiologiccator of the presence of coronary atherosclerosis. Based on these
interpretations, the authors conclude that total atherosclerotic
burden and not acute pathophysiologic effects of coronary disease
best predicts prognosis. This conclusion is further supported by
their observations that abnormal but not positive DSE influenced
ACM and that coronary interventions had no influence onCVMor
ACM. They speculate that the effect of total atherosclerotic burden
on CVM and ACM is mediated by clotting system activation
associated with plaque burden.
This conclusion, if proven valid, helps to explain the benefits
of antiplatelet agents and statins as modifiers of coagulation system
activation and plaque burden accumulation respectively, and may
guide the future development of novel secondary prevention strat-
egies.
While the limitations of this study (retrospective design,
highly selected cohort, exclusions, and use of “all-cause” mortality
as an endpoint) are obvious and acknowledged by the authors,
their finding that abnormal ABI is the more accurate predictor of
CVM and ACM is important and provocative. The implications of
this finding may be far-reaching but await validation by the au-
thors’ planned prospective study correlating CT measured total
body plaque burden, clotting system activation, and prognosis.
